Cetuximab (Targeted Therapy)
Treatment for Lip and oral cavity cancer
Typical Dosage: Loading dose 400 mg/m2, then 250 mg/m2 weekly
Effectiveness
65%
Safety Score
55%
Clinical Trials
2
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
Loading dose 400 mg/m2, then 250 mg/m2 weekly
Time to Effect
Weeks
Treatment Duration
Weekly for 7-8 weeks with RT, or until progression for metastatic
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$50,000
Monitoring:$8,000
Side Effect Mgmt:$3,000
Total Annual:$61,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$220,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$305,000
Cost per Remission
$1,220,000
Cetuximab (Targeted Therapy) Outcomes
for Lip and oral cavity cancer
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+20%
Remission Rate
+5%
Common Side Effects
Acneiform rash
+75%
Hypomagnesemia
+40%
Fatigue
+40%
Infusion reactions
+15%
Paronychia
+15%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
1 completed trial for Cetuximab (Targeted Therapy) in Lip and oral cavity cancer
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
NCT03082534COMPLETEDPHASE2
78 participants
INTERVENTIONAL
La Jolla, United States +3 more
Started: Mar 28, 2017